Table 5.
Correlation of MYC expression in tumor tissues with clinical parameters of PCa patients
| Clinical characteristics | n = 38 | MYC IHC score | p-Value | ||
|---|---|---|---|---|---|
| High (n = 19) | Low (n = 19) | ||||
| Age (years) | ≥ 66 | 17 | 8 | 9 | 0.7442 |
| < 66 | 21 | 11 | 10 | ||
| PSA (ng/mL) | ≥ 9.67 | 13 | 6 | 7 | 0.7324 |
| < 9.67 | 25 | 13 | 12 | ||
| Gleason score | ≤ 6 | 11 | 1 | 10 | 0.0012* |
| 3 + 4 | 10 | 6 | 4 | ||
| 4 + 3 | 9 | 4 | 5 | ||
| ≥ 8 | 8 | 8 | 0 | ||
| AR status | Positive | 30 | 13 | 17 | 0.1115 |
| Negative | 8 | 6 | 2 | ||
| p53 status | Positive | 15 | 11 | 4 | 0.0202* |
| Negative | 23 | 8 | 15 | ||
| T stage | pT2 | 23 | 10 | 13 | 0.2911 |
| pT3 | 13 | 7 | 6 | ||
| pT4 | 2 | 2 | 0 | ||
| Lymph node metastasis | Absent | 27 | 10 | 17 | 0.0123* |
| Present | 11 | 9 | 2 | ||
Chi-square test was used to analyze the correlation between gene expression in PCa tumor tissues and clinical characteristics of patients. PCa: prostate cancer; PSA: prostate-specific antigen; AR: androgen receptor; IHC: immunohistochemistry; *p < 0.05